SNGX Stock Forecast: Soligenix, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.22
−8.29% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 26 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$5.6M
Ticker Nerd rank
26/ 100
Median analyst target
$1.38
Analysts covering
—
Revenue$0.0
Operating income−$2.9M
Net income−$2.8M
Free cash flow−$2.4M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−31.2%
1M
−37.1%
YTD
−83.6%
1Y
−82.7%
From 52W high
−86.7%
From 52W low
0.0%
$0.22
$1.65
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Soligenix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
26/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
69
Accruals
64
Issuance
35
Revisions
31
Volatility
30
Quality
26
Value
15
Momentum
5

Growth (69): Sales and profits are climbing, and climbing faster than before.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SNGX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SNGX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$0.50$1.00$1.50Jan 26Apr 26Jul 26Oct 26SNGXHigh $1.50Median $1.38Low $1.25

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Of the 10 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
16 July 2025Alliance Global PartnersMaintainsBuy$10 → $6.00
4 Dec 2020B. Riley FBRInitiatesBuy—
4 Dec 2020B. Riley SecuritiesInitiatesBuy$4.00
28 July 2020Dawson JamesDowngradeNeutral$3.00 → $2.00
31 Jan 2018H.C. WainwrightDowngradeNeutral—
31 Jan 2018HC Wainwright & Co.DowngradeNeutral—
14 Aug 2017Maxim GroupMaintainsBuy$4.00 → $5.00
17 July 2017H.C. WainwrightInitiatesBuy—
17 July 2017HC Wainwright & Co.InitiatesBuy—
7 Sept 2016Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SNGX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SNGX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Soligenix, Inc. returned −82.7% against +6.9% for the S&P 500, dividends included.

SNGX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26SNGXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SNGX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.9×

Cheaper than 75% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−127.4%

Higher than 11% of US stocks

Return on assets
−59.2%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Soligenix, Inc. has a market value of $5.6M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$11.0M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$10.8M.

  • Shares outstanding: 23.4M.

  • Soligenix, Inc. employs 13 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

SNGX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SNGXSoligenix, Inc.$5.6M26
CNSPCNS Pharmaceuticals, Inc.$5.2M15
VIVSVivoSim Labs, Inc.$5.3M25
ICUSeastar Medical Holding Corp.$5.0M26
NIKINiki Biosolutions, Inc.$4.9M9
TOVXTheriva Biologics, Inc.$5.5M30
CDIOCardio Diagnostics Holdings, Inc.$4.7M20

Take a look at SNGX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Soligenix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SNGX

How does Ticker Nerd's model rank SNGX?

As at 21 Nov 2026, Soligenix, Inc. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (69 of 100).

What is the SNGX stock forecast for 2030?

No analyst covering Soligenix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SNGX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.25 to $1.5 over the next 12 months.

How has SNGX stock performed over the past year?

Soligenix, Inc. returned -82.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Soligenix, Inc. do?

Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases and other conditions with unmet medical needs. Its core business is organized into two segments: Specialized BioTherapeutics and Public Health Solutions.

Company

About Soligenix, Inc.

Soligenix Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases and other conditions with unmet medical needs. Its core business is organized into two segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops treatments for orphan and inflammatory diseases, including cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Behçet’s disease. The Public Health Solutions segment works on vaccines and therapeutics for biodefense and infectious disease threats, including ricin exposure, Ebola, Marburg, and other emerging viral infections. Soligenix Inc. plays a niche role in the healthcare market by targeting areas where treatment options remain limited, combining rare disease development with medical countermeasure research.

CEO Dr. Christopher J. Schaber Ph.D. · 13 employees · United States · https://www.soligenix.com